TY - JOUR T1 - Retrospective screening of routine respiratory samples revealed undetected community transmission and missed intervention opportunities for SARS-CoV-2 in the United Kingdom JF - medRxiv DO - 10.1101/2020.08.18.20174623 SP - 2020.08.18.20174623 AU - Joseph G. Chappell AU - Theocharis Tsoleridis AU - Gemma Clark AU - Louise Berry AU - Nadine Holmes AU - Christopher Moore AU - Matthew Carlile AU - Fei Sang AU - Johnny Debebe AU - Victoria Wright AU - William L. Irving AU - Brian J. Thomson AU - Timothy C.J. Boswell AU - Iona Willingham AU - Amelia Joseph AU - Wendy Smith AU - Manjinder Khakh AU - Vicki M. Fleming AU - Michelle M. Lister AU - Hannah C. Howson-Wells AU - Edward C. Holmes AU - Matthew W. Loose AU - Jonathan K. Ball AU - C. Patrick McClure AU - on behalf of the COG-UK consortium Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/21/2020.08.18.20174623.abstract N2 - In the early phases of the SARS coronavirus type 2 (SARS-CoV-2) pandemic, testing focused on individuals fitting a strict case definition involving a limited set of symptoms together with an identified epidemiological risk, such as contact with an infected individual or travel to a high-risk area. To assess whether this impaired our ability to detect and control early introductions of the virus into the UK, we PCR-tested archival specimens collected on admission to a large UK teaching hospital who retrospectively were identified as having a clinical presentation compatible with COVID-19. In addition, we screened available archival specimens submitted for respiratory virus diagnosis, and dating back to early January 2020, for the presence of SARS-CoV-2 RNA. Our data provides evidence for widespread community circulation of SARS-CoV2 in early February 2020 and into March that was undetected at the time due to restrictive case definitions informing testing policy. Genome sequence data showed that many of these early cases were infected with a distinct lineage of the virus. Sequences obtained from the first officially recorded case in Nottinghamshire - a traveller returning from Daegu, South Korea – also clustered with these early UK sequences suggesting acquisition of the virus occurred in the UK and not Daegu. Analysis of a larger sample of sequences obtained in the Nottinghamshire area revealed multiple viral introductions, mainly in late February and through March. These data highlight the importance of timely and extensive community testing to prevent future widespread transmission of the virus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Medical Research Council UK (MR/R010307/1 and MR/S009434/1), which are both part of the EDCTP2 programme supported by the European Union, The University of Nottingham Campaign and Alumni Relations Office research donations award and the EU H2020 programme (Project 727393, PaleBlu). Whole genome sequencing of SARS-CoV-2 was funded by COG-UK; COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The COG-UK consortium was approved by the PHE Research Ethics and Governance Group (R&D NR0195)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequence data used in this study is available through the COG-UK consortium and GIS-AID initiative. ER -